Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAK Immune Cell Injection
- Development stage
- Unknown
- Lead developer
- Beijing Tuohua Weiye Biotechnology
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
MAK Immune Cell Injection is an autologous or allogeneic cell therapy consisting of Mixed Activated Killer (MAK) cells, developed by Beijing Tuohua Weiye Biotechnology. MAK cells are a heterogeneous population of immune effector cells, including T lymphocytes, Natural Killer (NK) cells, and NKT cells, which are activated and expanded *ex vivo* (typically using cytokines such as IL-2 and anti-CD3 antibodies) to enhance their anti-tumor cytolytic activity. The therapy is designed to treat advanced solid tumors, particularly hepatocellular carcinoma, by leveraging the broad-spectrum cytotoxic capabilities of these activated immune cells to target and eliminate malignant cells. It is currently being evaluated in Phase I/IIa clinical trials in China for patients who have failed or are intolerant to standard systemic therapies.
- Other names
- Mixed Activated Killer Immune Cell Injection
Beyond the preview
Go deeper on MAK Immune Cell Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAK Immune Cell Injection.